89 related articles for article (PubMed ID: 27718044)
21. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
Beck V; Herold H; Benge A; Luber B; Hutzler P; Tschesche H; Kessler H; Schmitt M; Geppert HG; Reuning U
Int J Biochem Cell Biol; 2005 Mar; 37(3):590-603. PubMed ID: 15618016
[TBL] [Abstract][Full Text] [Related]
22. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by beta3 integrin.
Faccio R; Novack DV; Zallone A; Ross FP; Teitelbaum SL
J Cell Biol; 2003 Aug; 162(3):499-509. PubMed ID: 12900398
[TBL] [Abstract][Full Text] [Related]
23. Osteoprotegerin induces podosome disassembly in osteoclasts through calcium, ERK, and p38 MAPK signaling pathways.
Zhao H; Liu X; Zou H; Dai N; Yao L; Gao Q; Liu W; Gu J; Yuan Y; Bian J; Liu Z
Cytokine; 2015 Feb; 71(2):199-206. PubMed ID: 25461399
[TBL] [Abstract][Full Text] [Related]
24. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin.
Choi Y; Kim E; Lee Y; Han MH; Kang IC
Proteomics; 2010 Jan; 10(1):72-80. PubMed ID: 19882657
[TBL] [Abstract][Full Text] [Related]
25. [Development, physiology, and cell activity of bone].
de Baat P; Heijboer MP; de Baat C
Ned Tijdschr Tandheelkd; 2005 Jul; 112(7):258-63. PubMed ID: 16047964
[TBL] [Abstract][Full Text] [Related]
26. Disruption of integrin-fibronectin complexes by allosteric but not ligand-mimetic inhibitors.
Mould AP; Craig SE; Byron SK; Humphries MJ; Jowitt TA
Biochem J; 2014 Dec; 464(3):301-13. PubMed ID: 25333419
[TBL] [Abstract][Full Text] [Related]
27. Glomerular mesangial cell adhesion to fibrinogen is mediated by alphavbeta3 integrin.
Fischer EG
Biochem Cell Biol; 2004 Oct; 82(5):597-601. PubMed ID: 15499389
[TBL] [Abstract][Full Text] [Related]
28. Integrin activation dynamics between the RGD-binding site and the headpiece hinge.
Puklin-Faucher E; Vogel V
J Biol Chem; 2009 Dec; 284(52):36557-36568. PubMed ID: 19762919
[TBL] [Abstract][Full Text] [Related]
29. Attachment of osteocyte cell processes to the bone matrix.
McNamara LM; Majeska RJ; Weinbaum S; Friedrich V; Schaffler MB
Anat Rec (Hoboken); 2009 Mar; 292(3):355-63. PubMed ID: 19248169
[TBL] [Abstract][Full Text] [Related]
30. Calcium signaling in osteoclast differentiation and bone resorption.
Kajiya H
Adv Exp Med Biol; 2012; 740():917-32. PubMed ID: 22453976
[TBL] [Abstract][Full Text] [Related]
31. DICAM inhibits osteoclast differentiation through attenuation of the integrin αVβ3 pathway.
Jung YK; Han SW; Kim GW; Jeong JH; Kim HJ; Choi JY
J Bone Miner Res; 2012 Sep; 27(9):2024-34. PubMed ID: 22492581
[TBL] [Abstract][Full Text] [Related]
32. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin.
Yokosaki Y; Tanaka K; Higashikawa F; Yamashita K; Eboshida A
Matrix Biol; 2005 Sep; 24(6):418-27. PubMed ID: 16005200
[TBL] [Abstract][Full Text] [Related]
33. Mapping of heparin/heparan sulfate binding sites on αvβ3 integrin by molecular docking.
Ballut L; Sapay N; Chautard E; Imberty A; Ricard-Blum S
J Mol Recognit; 2013 Feb; 26(2):76-85. PubMed ID: 23334915
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.
Fisher JE; Caulfield MP; Sato M; Quartuccio HA; Gould RJ; Garsky VM; Rodan GA; Rosenblatt M
Endocrinology; 1993 Mar; 132(3):1411-3. PubMed ID: 8440195
[TBL] [Abstract][Full Text] [Related]
35. Extracellular protons acidify osteoclasts, reduce cytosolic calcium, and promote expression of cell-matrix attachment structures.
Teti A; Blair HC; Schlesinger P; Grano M; Zambonin-Zallone A; Kahn AJ; Teitelbaum SL; Hruska KA
J Clin Invest; 1989 Sep; 84(3):773-80. PubMed ID: 2547838
[TBL] [Abstract][Full Text] [Related]
36. Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat.
Crippes BA; Engleman VW; Settle SL; Delarco J; Ornberg RL; Helfrich MH; Horton MA; Nickols GA
Endocrinology; 1996 Mar; 137(3):918-24. PubMed ID: 8603604
[TBL] [Abstract][Full Text] [Related]
37. Direct effect of calcium channel antagonists on osteoclast function: alterations in bone resorption and intracellular calcium concentrations.
Ritchie CK; Maercklein PB; Fitzpatrick LA
Endocrinology; 1994 Sep; 135(3):996-1003. PubMed ID: 8070395
[TBL] [Abstract][Full Text] [Related]
38. An allosteric Ca2+ binding site on the beta3-integrins that regulates the dissociation rate for RGD ligands.
Hu DD; Barbas CF; Smith JW
J Biol Chem; 1996 Sep; 271(36):21745-51. PubMed ID: 8702970
[TBL] [Abstract][Full Text] [Related]
39. Interactions of connective tissue cells with the extracellular matrix.
Horton MA
Bone; 1995 Aug; 17(2 Suppl):51S-53S. PubMed ID: 8579898
[TBL] [Abstract][Full Text] [Related]
40. Enhanced bone regeneration via multimodal actions of synthetic peptide SVVYGLR on osteoprogenitors and osteoclasts.
Egusa H; Kaneda Y; Akashi Y; Hamada Y; Matsumoto T; Saeki M; Thakor DK; Tabata Y; Matsuura N; Yatani H
Biomaterials; 2009 Sep; 30(27):4676-86. PubMed ID: 19520427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
